Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Thomas Andrew Butler |
IPO Date | April 16, 2021 |
Location | United States |
Headquarters | 900 Middlefield Road, Redwood City, CA, United States, 94063 |
Employees | 110 |
Sector | Healthcare |
Industry | Biotechnology |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
NA
NA
NA
NA
StockViz Staff
September 21, 2024
Any question? Send us an email